MAAS Diversified Financials · China · Insurance · Conglomerate · Thesis updated July 17, 2026

Maase swapped finance focus for a risky conglomerate bet

Insurance agency was about 93.1% of fiscal 2025 net revenue from continuing operations.
The old wealth management and claims adjusting businesses are gone.
Carve adds wild ginseng resources and bird's nest biotech.
Real Prospect moves Maase into smart technology, far from its old finance roots.
The VIE structure has been removed, cutting one major China-stock risk.

01 Running thesis

A cleaner structure, messier strategy

The bull case starts with a real cleanup. Maase says it no longer has any VIE structure. A VIE is a contract setup that lets a foreign-listed company control a China business without owning it directly. Removing that structure cuts a risk that has hurt many China-linked stocks.

The remaining insurance agency business is the steadier piece. It earns commissions and fees when it distributes life, health, and non-life insurance products. Long-term life policies can also bring renewal commissions if customers keep paying premiums.

The hard part is the pivot. Maase sold wealth management and claims adjusting, then bought health assets tied to wild ginseng and bird's nest processing, plus a smart-technology company. That could open higher-margin growth, but it also looks like a company jumping into unrelated fields before proving the old core is strong.

The next key test is simple: can the new Maase show real segment profit, not just deal activity. Investors need the first filings that include Carve and Real Prospect, clearer health margins, and proof that insurance can grow on its own.

Oct 2025→Maase reported a full strategy reset. It exited claims adjusting and wealth management, removed its VIE structures, and bought Carve Group and Real Prospect, which makes the story cleaner legally but riskier operationally.

Nov 2024▲The AIFU deal made insurance agency the largest business segment. That gave Maase a clearer operating base than the old wealth management model.

02 Business model

Commissions first, new bets second

Maase is a Cayman Islands holding company with operations mainly in China. Its main reported business in fiscal 2025 was insurance agency. It gets paid by insurance companies, usually as a percentage of premiums paid by customers.

Life and health insurance can be more valuable than one-year policies because some policies pay first-year commissions and smaller renewal commissions over time. Non-life policies are usually shorter term, so Maase has to keep selling new policies to keep revenue coming in.

The new health business comes from Carve Group. Carve indirectly owns a premium wild ginseng resource holder and Glyken, a bird's nest biotech company focused on enzymatic hydrolysis and peptide extraction. The tech business comes from Real Prospect, which owns Qingdao Youdian New Energy Technology and a 49% stake in Qingdao Huiju Laixi Intelligent Technology.

This model can break if the insurance agent base weakens, commission rates fall, or the new units fail to produce cash. It can also break if China rules on data, foreign capital, or overseas listings tighten again.

03 Product portfolio

What Maase now sells

Cash cow

Life and health insurance distribution

This is the main reported revenue base. Maase earns commissions and fees when customers buy policies through its network.

Steady

Non-life insurance distribution

This includes products such as accident, medical, travel, homeowner, and commercial insurance. Many policies are short term, so repeat selling matters.

Option

Wild ginseng resources

Carve Group gives Maase exposure to premium wild ginseng. The filing does not yet show a full public margin record for this new segment.

Growth engine

Bird's nest biotech products

Glyken focuses on enzymatic hydrolysis and peptide extraction for bird's nest products. This could be a higher-margin health angle, but it still needs proof.

Option

Smart-technology solutions

Real Prospect moves Maase into smart technology. The strategic fit with insurance and health is still an open question.

04 Business segments

The last clean revenue mix

Insurance agency93%modest

Wealth management7%declining

Fiscal 2025 continuing operations showed insurance agency at about 93.1% of net revenue and wealth management making up the rest. Wealth management was sold after year end, so the next mix should look very different once Carve and Real Prospect are included.

05 Risk factors

What could go wrong

Conglomerate drift

High impact · High odds

Maase moved from finance into wild ginseng, bird's nest biotech, and smart technology in a short period. These businesses do not share an obvious operating playbook. If management cannot integrate them, deal costs and distraction could eat the value of the insurance core.

We watchLook for separate revenue, gross margin, and operating profit for Carve and Real Prospect in the next annual report.

Insurance core slowdown

High impact · Medium odds

Insurance agency is still the main proven business. Revenue depends on policy sales, renewal behavior, agent productivity, and commission rates from insurance companies. A weak China consumer market or lower premium growth would hit this segment first.

We watchTrack insurance agency net revenue, renewal commissions, and any disclosure on agent count or agent productivity.

China regulatory pressure

High impact · Medium odds

The VIE risk has been reduced, but Maase is still based mainly in China. Data security, personal information, foreign capital flow, and overseas listing rules can still affect its operations and access to investors. A new approval need or data review could slow deals or funding.

We watchWatch for new PRC cybersecurity review notices, overseas listing approval disclosures, or cash transfer limits.

Health margins disappoint

Medium impact · Medium odds

The health story sounds premium, but the public record does not yet prove its economics inside Maase. Wild ginseng supply, product pricing, processing costs, and sales channels all matter. If margins are ordinary, the acquisition may not justify the strategy shift.

We watchWatch Carve revenue, gross margin, inventory levels, and customer concentration once disclosed.

Holding-company cash limits

Medium impact · Medium odds

Maase is a Cayman holding company, while most operations are in China. Even without VIE contracts, moving cash from China subsidiaries to the public company can face rules and tax friction. That matters if Maase needs cash for dividends, buybacks, or more deals.

We watchTrack cash held by the parent versus PRC subsidiaries and any dividend or loan movement between entities.

06 Quick answers

In one breath

What does Maase Inc. do now?

Maase now owns an insurance agency business, a health-products business tied to wild ginseng and bird's nest biotech, and a smart-technology business. It no longer runs its old wealth management or claims adjusting operations.

Why does the VIE change matter for MAAS?

A VIE is a contract structure often used by China-based companies listed abroad. Maase says it has terminated those arrangements, which removes one major structural risk, though China regulatory risk remains.

What is the biggest question for investors?

The biggest question is whether the new health and smart-technology assets can make money without hurting the insurance business. The first full filings that consolidate Carve and Real Prospect should answer a lot.